Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 6 Ovarian Neoplasms 4 Neoplasms 3 Endometrial Neoplasms 3 Pancreatic Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Bulbo-Spinal Atrophy, X-Linked 1 Biliary Tract Neoplasms 1 Advanced Breast Cancer 1 Adenocarcinoma of Lung 1

Interventions

Fulvestrant 19 Letrozole 8 Anastrozole 6 Capecitabine 5 palbociclib 4 olaparib 4 Paclitaxel 4 Injections 4 Goserelin 4 Docetaxel 4 pyrotinib 3 exemestane 3 trastuzumab deruxtecan 2 toripalimab 2 sacituzumab govitecan 2 ribociclib 2 eribulin 2 elacestrant 2 abemaciclib 2 Vinorelbine 2 Trastuzumab 2 FCN-437c 2 Everolimus 2 Dasatinib 2 Aromatase Inhibitors 2 Alpelisib 2 Albumin-Bound Paclitaxel 2 AZD9833 2 vandetanib 1 talazoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Breast Cancer × AZD5305 × Clear all

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡